{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T19:41:10Z","timestamp":1768160470808,"version":"3.49.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["D589BN00039"],"award-info":[{"award-number":["D589BN00039"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0207675","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T13:39:48Z","timestamp":1548337188000},"page":"e0207675","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1735-4046","authenticated-orcid":true,"given":"Karin A.","family":"Provost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Miller-Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D.","family":"Gudleski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1378\/chest.128.4.2005","article-title":"Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001","volume":"128","author":"F Holguin","year":"2005","journal-title":"Chest"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1183\/09031936.99.13234999","article-title":"Risk factors for community-acquired pneumonia in adults: a population-based case-control study","volume":"13","author":"J Almirall","year":"1999","journal-title":"Eur Respir J"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1378\/chest.116.2.375","article-title":"Proportion of community-acquired pneumonia cases attributable to tobacco smoking","volume":"116","author":"J Almirall","year":"1999","journal-title":"Chest"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"S Suissa","year":"2013","journal-title":"Thorax"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1378\/chest.09-2992","article-title":"Reported pneumonia in patients with COPD: findings from the INSPIRE study","volume":"139","author":"PM Calverley","year":"2011","journal-title":"Chest"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1164\/rccm.200611-1630OC","article-title":"Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia","volume":"176","author":"P Ernst","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results","volume":"34","author":"C Crim","year":"2009","journal-title":"Eur Respir J"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"JA Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"MT Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"23","key":"ref10","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","volume":"374","author":"JA Wedzicha","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1742-1241.2011.02685.x","article-title":"Budesonide\/formoterol vs. salmeterol\/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials","volume":"65","author":"DM Halpin","year":"2011","journal-title":"Int J Clin Pract"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"f3306","DOI":"10.1136\/bmj.f3306","article-title":"Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS)","volume":"346","author":"C Janson","year":"2013","journal-title":"Bmj"},{"key":"ref13","article-title":"Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study","author":"JB Morjaria","year":"2017","journal-title":"Lung"},{"issue":"9356","key":"ref14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"P Calverley","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"W Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"ref16","article-title":"Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia","author":"S Suissa","year":"2015","journal-title":"Chest"},{"issue":"14","key":"ref17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"H Magnussen","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study","volume":"166","author":"P van der Valk","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/thx.2004.034280","article-title":"Withdrawal of fluticasone propionate from combined salmeterol\/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial","volume":"60","author":"EF Wouters","year":"2005","journal-title":"Thorax"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1034\/j.1398-9995.1999.00087.x","article-title":"Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages","volume":"54","author":"A Ek","year":"1999","journal-title":"Allergy"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/08958370903521216","article-title":"Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells","volume":"22","author":"I von Scheele","year":"2010","journal-title":"Inhalation toxicology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/COPD.S102668","article-title":"Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD","volume":"11","author":"J Ji","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-8-84","article-title":"Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke","volume":"8","author":"RE MacRedmond","year":"2007","journal-title":"Respiratory Research"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1086\/508428","article-title":"Impaired Phagocytosis of Nontypeable Haemophilus influenzae by Human Alveolar Macrophages in Chronic Obstructive Pulmonary Disease","volume":"194","author":"CS Berenson","year":"2006","journal-title":"The Journal of Infectious Diseases"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1164\/rccm.200509-1461OC","article-title":"Impaired Alveolar Macrophage Response to Haemophilus Antigens in Chronic Obstructive Lung Disease","volume":"174","author":"CS Berenson","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/thoraxjnl-2013-203669","article-title":"Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations","volume":"69","author":"CS Berenson","year":"2014","journal-title":"Thorax"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1440-1711.2003.t01-1-01170.x","article-title":"Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells","volume":"81","author":"S Hodge","year":"2003","journal-title":"Immunol Cell Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1165\/rcmb.2007-0025OC","article-title":"Smoking Alters Alveolar Macrophage Recognition and Phagocytic Ability","volume":"37","author":"S Hodge","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1183\/09031936.00036709","article-title":"Defective macrophage phagocytosis of bacteria in COPD","volume":"35","author":"AE Taylor","year":"2010","journal-title":"The European Respiratory Journal"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1165\/rcmb.2014-0172OC","article-title":"Calcium restores the macrophage response to nontypeable haemophilus influenzae in chronic obstructive pulmonary disease","volume":"52","author":"KA Provost","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/01902140802366261","article-title":"In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function","volume":"34","author":"AR Winkler","year":"2008","journal-title":"Exp Lung Res"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/thoraxjnl-2017-210722","article-title":"Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years","volume":"73","author":"SP Bhatt","year":"2018","journal-title":"Thorax"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2147\/COPD.S82259","article-title":"Smoking duration, respiratory symptoms, and COPD in adults aged >\/ = 45 years with a smoking history","volume":"10","author":"Y Liu","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/infdis\/jit400","article-title":"Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease","volume":"208","author":"CS Berenson","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1165\/rcmb.2009-0459OC","article-title":"Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine","volume":"44","author":"S Hodge","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-015-0458-6","article-title":"Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes","volume":"12","author":"C Marinelli","year":"2015","journal-title":"J Neuroinflammation"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12865-014-0055-y","article-title":"The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases","volume":"15","author":"J Ten Oever","year":"2014","journal-title":"BMC immunology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1465-9921-6-68","article-title":"Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients","volume":"6","author":"D Droemann","year":"2005","journal-title":"Respir Res"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.05.00062304","article-title":"Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD","volume":"25","author":"AR Pons","year":"2005","journal-title":"Eur Respir J"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.1365-2249.1996.d01-805.x","article-title":"Chronic smoke exposure alters the phenotype pattern and the metabolic response in human alveolar macrophages","volume":"106","author":"CM Skold","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2249.2006.03154.x","article-title":"Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers","volume":"145","author":"JM Lofdahl","year":"2006","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"ref42","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4049\/jimmunol.1700140","article-title":"Aging-Impaired Filamentous Actin Polymerization Signaling Reduces Alveolar Macrophage Phagocytosis of Bacteria","volume":"199","author":"Z Li","year":"2017","journal-title":"J Immunol"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2008.03164.x","article-title":"Evidence of the in vivo esterification of budesonide in human airways","volume":"66","author":"KI Maassen van den Brink","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4049\/jimmunol.1202113","article-title":"MARCO is required for TLR2- and Nod2-mediated responses to Streptococcus pneumoniae and clearance of pneumococcal colonization in the murine nasopharynx","volume":"190","author":"MG Dorrington","year":"2013","journal-title":"J Immunol"},{"issue":"78","key":"ref45","doi-asserted-by":"crossref","first-page":"78ra32","DOI":"10.1126\/scitranslmed.3002042","article-title":"Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model","volume":"3","author":"CJ Harvey","year":"2011","journal-title":"Science translational medicine"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajpath.2011.09.029","article-title":"Elastase\/LPS-exposed mice exhibit impaired innate immune responses to bacterial challenge: role of scavenger receptor A","volume":"180","author":"S Ganesan","year":"2012","journal-title":"Am J Pathol"},{"issue":"7","key":"ref47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1399-6576.2004.00434.x","article-title":"Glucocorticoid regulation of the inflammatory response to injury","volume":"48","author":"MP Yeager","year":"2004","journal-title":"Acta Anaesthesiol Scand"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0207675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:13:11Z","timestamp":1588965191000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0207675"}},"subtitle":[],"editor":[{"given":"Fabio Luigi Massimo","family":"Ricciardolo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0207675","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]}}}